Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine and Moxifloxacin Short-Course Regimens for Mild Spinal Tuberculosis
NCT06917495Phase 2Not yet recruiting
- Sponsor
- Shandong University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifapentine and moxifloxacin in spinal tuberculosis (2 arms), sponsored by Shandong University. Primary endpoints: TB-recurrence rate of spinal tuberculosis and Proportion of participants with grade 3 or more adverse events at 36 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
spinal tuberculosis
Beyond the preview
Go deeper on NCT06917495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917495.